Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
Replimune Group, Inc. (REPL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/24/2023 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 18,600 shares
@ $20.01, valued at
$372.2k
Exercised 13,600 options to buy
@ $3.3, valued at
$44.9k
Exercised 5,000 options to buy
@ $15.5, valued at
$77.5k
|
|
08/15/2023 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 1,400 shares
@ $20, valued at
$28k
Exercised 1,400 options to buy
@ $3.3, valued at
$4.6k
|
|
07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/15/2023 |
4
| Lewis Tanya (Chief Dev. Op. Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 12,043 shares
@ $24.1, valued at
$290.2k
Sold 817 shares
@ $23.45, valued at
$19.2k
|
|
06/15/2023 |
4
| Patel Sushil (Chief Strategy Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 5,145 shares
@ $24.11, valued at
$124k
Sold 553 shares
@ $23.44, valued at
$13k
|
|
05/18/2023 |
4
| Patel Sushil (Chief Strategy Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 15,575 shares
@ $18.05, valued at
$281.1k
|
|
05/18/2023 |
4
| Coffin Robert (President & Chief R&D Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 7,861 shares
@ $18.05, valued at
$141.9k
|
|
05/18/2023 |
4
| Lewis Tanya (Chief Dev. Op. Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 12,207 shares
@ $18.05, valued at
$220.3k
|
|
05/18/2023 |
4
| Love Colin (COO) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 10,775 shares
@ $18.05, valued at
$194.5k
|
|
05/18/2023 |
4
| Franchi Jean M. (CFO) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 11,351 shares
@ $18.05, valued at
$204.9k
|
|
05/18/2023 |
4
| Xynos Konstantinos (Chief Medical Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 771 shares
@ $18.05, valued at
$13.9k
|
|
05/18/2023 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 5,966 shares
@ $18.05, valued at
$107.7k
|
|
05/18/2023 |
4
| Astley-Sparke Philip (CEO) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 17,902 shares
@ $18.05, valued at
$323.1k
|
|
04/04/2023 |
4
| Slootweg Hugo Alexander (Director) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
04/04/2023 |
4
| Pucci Paolo (Director) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
04/04/2023 |
4
| Dhingra Kapil (Director) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
04/04/2023 |
4
| SLATTERY JOSEPH P (Director) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
04/04/2023 |
4
| Levitsky Hyam (Director) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
04/04/2023 |
4
| Weinand Dieter (Director) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 37,800 options to buy
@ $17.66, valued at
$667.5k
|
|
04/04/2023 |
4
| Oliger Christy J. (Director) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 25,200 options to buy
@ $17.66, valued at
$445k
|
|
04/04/2023 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 40,000 shares
@ $0 Granted 60,000 options to buy
@ $17.66, valued at
$1.1M
|
|
04/04/2023 |
4
| Xynos Konstantinos (Chief Medical Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 50,000 shares
@ $0 Granted 75,000 options to buy
@ $17.66, valued at
$1.3M
|
|
04/04/2023 |
4
| Franchi Jean M. (CFO) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 45,000 shares
@ $0 Granted 67,500 options to buy
@ $17.66, valued at
$1.2M
|
|
04/04/2023 |
4
| Love Colin (COO) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 40,000 shares
@ $0 Granted 60,000 options to buy
@ $17.66, valued at
$1.1M
|
|
04/04/2023 |
4
| Lewis Tanya (Chief Dev. Op. Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 40,000 shares
@ $0 Granted 60,000 options to buy
@ $17.66, valued at
$1.1M
|
|
04/04/2023 |
4
| Patel Sushil (Chief Strategy Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 40,000 shares
@ $0 Granted 60,000 options to buy
@ $17.66, valued at
$1.1M
|
|
04/04/2023 |
4
| Coffin Robert (President & Chief R&D Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 45,000 shares
@ $0 Granted 67,500 options to buy
@ $17.66, valued at
$1.2M
|
|
04/04/2023 |
4
| Astley-Sparke Philip (CEO) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Granted 142,100 shares
@ $0 Granted 213,150 options to buy
@ $17.66, valued at
$3.8M
|
|
12/13/2022 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 15,000 shares
@ $25.03, valued at
$375.5k
Exercised 15,000 options to buy
@ $1.01, valued at
$15.2k
|
|
12/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/18/2022 |
4
| Love Colin (COO) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 6,324 shares
@ $14.59, valued at
$92.3k
|
|
05/18/2022 |
4
| Esposito Pamela (Chief Business Officer) has filed a Form 4 on Replimune Group, Inc.
Txns:
| Sold 3,507 shares
@ $14.59, valued at
$51.2k
|
|
05/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|